'On consolidated basis
Quarter ended March 2025 compared with Quarter ended March 2024.
Net sales (including other operating income) of Aurobindo Pharma has increased 10.58% to Rs 8382.12 crore. Operating profit margin has declined from 22.07% to 21.38%, leading to 7.12% rise in operating profit to Rs 1,791.92 crore. Raw material cost as a % of total sales (net of stock adjustments) increased from 33.18% to 33.37%. Purchase of finished goods cost fell from 9.90% to 7.58%. Employee cost increased from 12.93% to 13.86%. Other expenses rose from 22.92% to 23.83%.
Other income fell 0.60% to Rs 134.81 crore. PBIDT rose 6.54% to Rs 1926.73 crore. Provision for interest rose 28.61% to Rs 115.02 crore. Loan funds rose to Rs 8,262.87 crore as of 31 March 2025 from Rs 6,647.63 crore as of 31 March 2024. Inventories rose to Rs 10,543.72 crore as of 3...
Pleaselogin & subscribe to view the full report.
More Reports
|
|